These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9433537)

  • 1. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
    Holden JA
    Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
    Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
    Staley BE; Samowitz WS; Bronstein IB; Holden JA
    Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas.
    Bauman ME; Holden JA; Brown KA; Harker WG; Perkins SL
    Mod Pathol; 1997 Mar; 10(3):168-75. PubMed ID: 9071722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging DNA topisomerase inhibitors as anticancer drugs.
    Denny WA
    Expert Opin Emerg Drugs; 2004 May; 9(1):105-33. PubMed ID: 15155139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
    Valkov NI; Sullivan DM
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues.
    Holden JA; Snow GW; Perkins SL; Jolles CJ; Kjeldsberg CR
    Mod Pathol; 1994 Oct; 7(8):829-34. PubMed ID: 7838837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
    Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
    Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
    Boege F
    Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
    Coleman LW; Bronstein IB; Holden JA
    Anticancer Res; 2001; 21(2A):1167-72. PubMed ID: 11396158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Yoshida M
    Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
    Withoff S; De Jong S; De Vries EG; Mulder NH
    Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.